Zhize Tongkang (Guangzhou) Biotechnology prepares new anti-CLDN6 ADCs
May 29, 2026
Zhize Tongkang (Guangzhou) Biotechnology Co. Ltd. has divulged new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting claudin 6 (CLDN6) linked to a camptothecin derivative potentially useful for the treatment of cancer and fibrosis.